On October 2, United Therapeutics fell 5.19% in regular trading, trading at $542.915 USD/share, with Turnover of $295 million.

Within the Biotechnology sector where United Therapeutics belongs, individual stock performance was mixed. Among individual stocks, Insmed up 1.36%, AbbVie up 0.89%, Natera down 0.22%, Moderna down 0.42%, Amgen down 0.71%.

United Therapeutics Corporation is a biotechnology company that engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases. The company offers Tyvaso DPI, Tyvaso inhalation solution, Remodulin injection, Orenitram, and Adcirca for pulmonary arterial hypertension, as well as Unituxin for high-risk neuroblastoma. It is also developing ralinepag for PAH and nebulized Tyvaso for idiopathic pulmonary fibrosis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)